Biocon

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Biocon Limited
Public
Traded asBSE532523
NSEBIOCON
ISININE376G01013 Edit this on Wikidata
IndustryBiotechnology
Founded1978
FounderKiran Mazumdar-Shaw
Headquarters,
Key people
Kiran Mazumdar-Shaw
(Chairperson & MD)

Arun Chandavarkar
(CEO & Joint Managing Director)

ProductsBiologics
Small Molecules
Branded Formulations
Research Services
RevenueIncrease 4,079 crore (US$590 million) (2016–17) [1]
Number of employees
9,234 (Mar 2017)[1]
SubsidiariesSyngene
Websitewww.biocon.com

Biocon Limited (BSE532523) is an Indian biopharmaceutical company based in Bangalore, India.[2] The Company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries [no proof provided] across the globe, including the developed markets of the United States and Europe.[2] It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets [provide reference]. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon.

Biocon's formulations for the Indian market include Metabolics, Oncology, Immunotherapy, Nephrology and Specialty. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb(Itolizumab) and KRABEVA (Bevacizumab).[2]

Biocon and Syngene together employ about 9200 personnel.[2]

On 3rd Dec'19, Siddharth Mittal takes over from Dr Arun Chandavarkar who retired as Chief Executive Officer & Joint Managing Director of Biocon on November 30, 2019, after 29 years of contribution to the evolution and success of Biocon.[3]

History[edit]

Biocon was founded in 1978 with 10,000 (US$140) as the initial capital.[4]

Biocon's first product to go to market was papain, an enzyme found in papaya which is used to prevent beer from turning hazy.[5] Until 1983, the company blended enzymes and supplied them to brewing, textiles, biofuels, animal feed and other such industries across the world.

In 1989, the Irish Biocon was acquired by Unilever.

Biocon's milestone events in each year are as follows:[6]

  • 29 November 1978 - Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and Kiran Mazumdar-Shaw.[7]
  • 1979 - Becomes the first Indian company to manufacture and export enzymes to USA and Europe.[8]
  • 1989 - Unilever acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.[5]
  • 1994 - Establishes Syngene International Pvt. Ltd. as a Custom Research Company (CRC).[5]
  • 1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.[9]
  • 2001 - Becomes the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.[10]
  • 2003 - Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.[11]
  • 2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and Dr. APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".[12]
  • * 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.[13]
  • 2009 - Syngene-Bristol Myers Squibb research facility is established in Bengaluru.[14]
  • 2009 - Mylan announces strategic collaboration with Biocon to Enter the Global Generic Biologics Market.[15]
  • 2010 - Biocon expands to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.[16]
  • 2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device.[17]
  • 2012 - Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.[18]
  • 2013 - Biocon launches biologic drug ALZUMAb to treat psoriasis.[19]
  • 2014 - Biocon launches world's first biosimilar drug CANMAb to treat breast cancer.[20]
  • 2015 - Biocon launches hepatitis-C drug in India under brand name CIMIVIR-L.[21]
  • 2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.[22]
  • 2016 - Syngene sets up Amgen R&D center in Bangalore.[23]
  • 2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.[24]
  • 2017 - USFDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin.[25]
  • 2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.[26]

Corporate Governance[edit]

Kiran Mazumdar-Shaw is an Indian entrepreneur. She founded Biocon in 1978.

Biocon's CMD Kiran Mazumdar–Shaw joined Biocon in 1978.[6][27][28]

Her efforts in biotechnology have drawn global recognition both for the industry in India and for Biocon and she has been termed India's Biotech Queen by The Economist[29] and India's mother of invention by The New York Times.[30] She was recently named among TIME magazine's 100 most influential people in the world based not only on her contribution to the biotech industry but also because she gives back to the community.[31] Ms Shaw features on the Forbes list of ‘The World’s 100 Most Powerful Women’[32] and in Financial Times’ ‘Top 50 Women in Business’ list[33]

Ms. Shaw is the recipient of several awards including the Nikkei Asia Prize, 2009 for Regional Growth,[34] Express Pharmaceutical Leadership Summit Award 2009 for Dynamic Entrepreneur, The Economic Times ‘Businesswoman of the Year’, the ‘Veuve Clicquot Initiative For Economic Development For Asia, Ernst & Young’s Entrepreneur of the Year Award for Life Sciences & Healthcare, ‘Technology Pioneer’ recognition by World Economic Forum and The Indian Chamber of Commerce Lifetime Achievement Award. She has received two Indian national awards—Padma Shri (1989) and Padma Bhushan (2005) for her pioneering efforts in Industrial Biotechnology.[6]

Born on 23 March 1953 in Bangalore, Ms. Shaw received a graduate honours degree in Zoology from Bangalore University (1973) and qualified as a Master Brewer from Ballarat University, Australia (1975). She received an honorary Doctorate of Science in 2004 from Ballarat University in recognition of her contributions to biotechnology.[6] Biocon announced that Dr. Christiane Hamacher has been appointed as the CEO of Biocon Biologic India Limited effective from March 2019.[35]

Subsidiaries, Acquisitions and Strategic Global Alliances[edit]

Syngene International Ltd[edit]

Established in 1993, Syngene International Limited is Biocon's custom research organisation offering pharmaceutical and biotechnology majors customised solutions in synthetic chemistry and molecular biology for early-stage drug discovery and development.

Clinigene[edit]

Clinigene International Limited is a subsidiary on Syngene offering international pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic molecules.[6]

BBPL[edit]

Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint venture with the Cuban institute CIMAB to develop and market a range of MAbs and cancer vaccines.[6]

Biocon-AxiCorp[edit]

In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German pharmaceutical marketing company.

NeoBiocon[edit]

Incorporated in January 2008 NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi.

Biocon and Amylin[edit]

In 2009, Biocon and Amylin Pharmaceuticals of the United States entered into an agreement to develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin provides expertise in peptide hormone development, particularly in the area of phybrid technology and metabolic disease therapeutics. Biocon will utilise its expertise in recombinant microbial expression and experience in preclinical and clinical development of diabetes products to manufacture the compound.[6]

Biocon and IATRICa[edit]

In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies are co-developing candidate products based upon IATRICa's technology platform and Biocon's expertise in drug development, biologics manufacturing, and clinical research. The goal of this collaboration is to develop a therapeutic vaccine where the T cell mediated immunity is enhanced and maintained against a tumor which otherwise evades immune responses. Methods of developing, characterising and scaling up of conjugated monoclonal antibody production are being currently studied.[6]

Biocon and Mylan[edit]

In 2009, Biocon signed a collaboration agreement with Mylan to develop and commercialize generic biologics. Mylan and Biocon will share development, capital and other costs to bring products to market. Mylan will have exclusive commercialisation rights in USA, Canada, Japan, Australia, New Zealand, EU and European Free Trade Association countries through a profit sharing arrangement with Biocon.[6]

Biocon and Optimer[edit]

Biocon and Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of serious infections such as Clostridium Difficile Infection (CDI), have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient, fidaxomicin.,[2][6]

Biocon and Vaccinex[edit]

Biocon is also developing fully human antibodies BVX 10 and BVX-20 with a US antibody technology partner, Vaccinex. The partnership was initiated in 2004. BVX 10 targets TNF (Tumor Necrosis Factor) which is expressed at high levels in patients suffering from rheumatoid arthritis. Biocon's strategic partnership with Vaccinex allows access to their proprietary human antibody platform technology, thereby providing a strong IP protection to Biocon's antibody pipeline.,[2][6]

Biocon and Abraxis[edit]

In 2007, Biocon and Abraxis BioScience, Inc. entered into an agreement which helped Biocon out-license the rights to develop and market a biosimilar version of GCSF (Granulocyte Colony-Stimulating Factor) to North American and European markets.[6]

Biocon and Sandoz[edit]

In January 2018, Sandoz (a Novartis division) announced a global partnership with Biocon to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. .[36]

Biocon Technology[edit]

Biocon's manufacturing facilities are located at two sites in Bangalore.[6]

Research & Development Capabilities[edit]

Biocon's discovery-led R&D focuses on the entire drug development pathway – from process development, to non-clinical and clinical research.[6]

Products[edit]

Biocon's portfolio consists of 36 brands across the four therapeutic divisions of Diabetology, Nephrology, Oncology and Cardiology.[2]

References[edit]

  1. ^ a b "Biocon Annual Report 2017" (PDF). Biocon.
  2. ^ a b c d e f g "Biocon Annual Report, 2010" (PDF). Archived from the original (PDF) on 26 October 2010. Retrieved 20 September 2010.
  3. ^ "Biocon names Siddharth Mittal as new CEO, Joint MD; bids farewell to Arun Chandavarkar". Medical Dialogues. 3 December 2019.
  4. ^ [1], The Hindu, Metro Plus, 27 April 2010 Archived 2 May 2010 at the Wayback Machine
  5. ^ a b c Kiran Mazumdar-Shaw, CMD, Biocon Ltd, ‘Biotech Is Not for Punters’, Outlook Money, 15 July 2004
  6. ^ a b c d e f g h i j k l m n Biocon Website ("Archived copy". Archived from the original on 7 August 2014. Retrieved 2014-08-03.CS1 maint: archived copy as title (link))
  7. ^ "We need meritocracy, not mediocrity". theweek.in. Retrieved 8 February 2018.
  8. ^ nimmi. "Biocon, India's largest biotech company". www.indianmirror.com. Retrieved 8 February 2018.
  9. ^ Baisya, Rajat K. (9 September 2010). Winning Strategies for Business. SAGE Publications India. ISBN 9788132106081.
  10. ^ Pearce (2009). Strategic Management 10E. McGraw-Hill Education (India) Pvt Limited. ISBN 9780070264380.
  11. ^ "Biocon Ltd: About Biocon Pharma Company Founder, CEO, Products & Contact Address". www.brandindiapharma.in. Retrieved 8 February 2018.
  12. ^ "Dr. APJ Abdul Kalam Dedicates India\'s First Cancer Drug BIOMab EGFR to the Nation and Inaugurates India\'s Largest Biotech-Hub "Biocon Park" | Evaluate". www.evaluategroup.com. Retrieved 8 February 2018.
  13. ^ "Biocon Acquires 70% Stake in German Pharmaceutical Company, AxiCorp: Biosimilars Will be Main Focus | Evaluate". www.evaluategroup.com. Retrieved 8 February 2018.
  14. ^ Burns, Lawton R. (13 January 2014). India's Healthcare Industry: Innovation in Delivery, Financing, and Manufacturing. Cambridge University Press. ISBN 9781107044371.
  15. ^ "Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market". MediaRoom. Retrieved 8 February 2018.
  16. ^ "Biocon Limited To Build US$161 Million R&D Facility in Bio-XCell, Malaysia". Asian Scientist Magazine | Science, technology and medical news updates from Asia. 11 September 2011. Retrieved 8 February 2018.
  17. ^ "Biocon Launches INSUPen®, a Convenient and Affordable Reusable Insulin Delivery Device | Evaluate". www.evaluategroup.com. Retrieved 8 February 2018.
  18. ^ Abbott. "Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India". prnewswire.com. Retrieved 8 February 2018.
  19. ^ "Biocon unveils biologic drug to treat skin disorder". @businessline. Retrieved 8 February 2018.
  20. ^ "Kiran Mazumdar-Shaw's Biocon develops new breast cancer drug". indiatimes.com. 18 January 2014. Retrieved 19 January 2014.
  21. ^ Pilla, Viswanath (24 December 2015). "Biocon launches hepatitis-C drug in India". livemint.com/. Retrieved 8 February 2018.
  22. ^ Pilla, Viswanath (15 July 2016). "Biocon's partner FUJIFILM launches insulin glargine in Japan". livemint.com/. Retrieved 20 December 2017.
  23. ^ "Indian CRO Syngene sets up Amgen R&D center in Bangalore | FierceBiotech". www.fiercebiotech.com. Retrieved 8 February 2018.
  24. ^ "Biocon Wins MYR 300 Million Contract For Insulin From MoH Malaysia". www.biosimilardevelopment.com. Retrieved 20 December 2017.
  25. ^ Trivedi, Isha (2 December 2017). "US FDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin". livemint.com/. Retrieved 8 February 2018.
  26. ^ "Biocon, Mylan get European Commission approval to market biosimilar insulin glargine". Business Medical Dialogues. 30 March 2018.
  27. ^ Nature Reviews Drug Discovery, July 2010
  28. ^ Biospectrum India Friday, 11 July 2008
  29. ^ Kiran Mazumdar Shaw, India's fermentation queen, 30 August 2001
  30. ^ "How India's Mother of Invention Built an Industry", 16 August 2003
  31. ^ Time, 29 April 2010
  32. ^ The World's 100 Most Powerful Women, Forbes, 19 August 2009
  33. ^ FT top 50 women in world business, Financial Times, 25 September 2009
  34. ^ The Hindu, 12 May 2009
  35. ^ "Biocon appoints Christiane Hamacher as CEO of Biocon Biologics India". Medical Dialogues. 2 March 2019.
  36. ^ "Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars | Novartis". Novartis. Retrieved 8 February 2018.